Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Single agents vs combination chemotherapy in relapsed and refractory peripheral T-cell lymphoma: Results from the comprehensive oncology measures for peripheral T-cell lymphoma treatment (COMPLETE) registry.
Stuver RN, Khan N, Schwartz M, Acosta M, Federico M, Gisselbrecht C, Horwitz SM, Lansigan F, Pinter-Brown LC, Pro B, Shustov AR, Foss FM, Jain S. Stuver RN, et al. Am J Hematol. 2019 Jun;94(6):641-649. doi: 10.1002/ajh.25463. Epub 2019 Apr 9. Am J Hematol. 2019. PMID: 30896890 Free PMC article. Clinical Trial.
Current Treatment of Peripheral T-cell Lymphoma.
Stuver R, Epstein-Peterson ZD, Johnson WT, Khan N, Lewis N, Moskowitz AJ, Sauter CS, Horwitz S. Stuver R, et al. Oncology (Williston Park). 2022 May 9;36(5):293-305. doi: 10.46883/2022.25920960. Oncology (Williston Park). 2022. PMID: 35576176
Comparative outcomes for mature T-cell and NK/T-cell lymphomas in people with and without HIV and to AIDS-defining lymphomas.
Koh MJ, Merrill MH, Koh MJ, Stuver R, Alonso CD, Foss FM, Mayor AM, Gill J, Epeldegui M, Cachay E, Thorne JE, Silverberg MJ, Horberg MA, Althoff KN, Nijhawan AE, McGinnis KA, Lee JS, Rabkin CS, Napravnik S, Li J, Castilho JL, Shen C, Jain S. Koh MJ, et al. Among authors: stuver r. Blood Adv. 2022 Mar 8;6(5):1420-1431. doi: 10.1182/bloodadvances.2021006208. Blood Adv. 2022. PMID: 35026839 Free PMC article.
Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies.
Stuver R, Shah GL, Korde NS, Roeker LE, Mato AR, Batlevi CL, Chung DJ, Doddi S, Falchi L, Gyurkocza B, Hamilton A, Lin YH, Jakubowski AA, Joffe E, Landau HL, Lin RJ, Mailankody S, Palomba ML, Park JH, Perales MA, Ponce DM, Ramanathan LV, Salles GA, Scordo M, Seo SK, Shah UA, Stein EM, Straus D, Usmani SZ, Young JW, Zelenetz AD, Noy A, Vardhana SA. Stuver R, et al. Cancer Cell. 2022 Jun 13;40(6):590-591. doi: 10.1016/j.ccell.2022.05.007. Epub 2022 May 16. Cancer Cell. 2022. PMID: 35598602 Free PMC article. No abstract available.
Phase II Trial of Nivolumab Plus Doxorubicin, Vinblastine, Dacarbazine as Frontline Therapy in Older Adults With Hodgkin Lymphoma.
Torka P, Feldman T, Savage KJ, Ganesan N, Drill E, Hancock H, Davey T, Perez L, Capadona C, Subzwari S, Galasso N, Yang J, Post M, Boardman A, Caron P, David K, Epstein-Peterson Z, Falchi L, Ghione P, Hamlin P, Horwitz SM, Intlekofer AM, Johnson W, Kumar A, Lue J, Noy A, Owens C, Palomba ML, Salles GA, Steiner R, Stuver R, Vardhana S, Yahalom J, Dogan A, Zelenetz AD, Schöder H, Moskowitz AJ. Torka P, et al. Among authors: stuver r. J Clin Oncol. 2024 Dec 11:JCO2401278. doi: 10.1200/JCO-24-01278. Online ahead of print. J Clin Oncol. 2024. PMID: 39661923
31 results